Knights of Columbus Asset Advisors LLC Has $1.31 Million Position in Exact Sciences Co. (NASDAQ:EXAS)

Knights of Columbus Asset Advisors LLC boosted its stake in shares of Exact Sciences Co. (NASDAQ:EXAS) by 7.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 23,298 shares of the medical research company’s stock after buying an additional 1,692 shares during the quarter. Knights of Columbus Asset Advisors LLC’s holdings in Exact Sciences were worth $1,309,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of EXAS. Perigon Wealth Management LLC raised its position in shares of Exact Sciences by 3.2% in the 4th quarter. Perigon Wealth Management LLC now owns 8,436 shares of the medical research company’s stock worth $474,000 after acquiring an additional 264 shares in the last quarter. Sanctuary Advisors LLC raised its position in shares of Exact Sciences by 2.0% in the 4th quarter. Sanctuary Advisors LLC now owns 13,625 shares of the medical research company’s stock worth $763,000 after acquiring an additional 269 shares in the last quarter. Daiwa Securities Group Inc. raised its position in shares of Exact Sciences by 2.1% in the 4th quarter. Daiwa Securities Group Inc. now owns 14,447 shares of the medical research company’s stock worth $812,000 after acquiring an additional 300 shares in the last quarter. Advisors Asset Management Inc. raised its position in shares of Exact Sciences by 1.4% in the 3rd quarter. Advisors Asset Management Inc. now owns 28,650 shares of the medical research company’s stock worth $1,952,000 after acquiring an additional 402 shares in the last quarter. Finally, Intech Investment Management LLC raised its position in shares of Exact Sciences by 3.5% in the 3rd quarter. Intech Investment Management LLC now owns 11,986 shares of the medical research company’s stock worth $816,000 after acquiring an additional 402 shares in the last quarter. 88.82% of the stock is owned by institutional investors and hedge funds.

Exact Sciences Price Performance

Shares of NASDAQ EXAS opened at $45.62 on Friday. Exact Sciences Co. has a twelve month low of $40.62 and a twelve month high of $79.62. The stock’s 50 day moving average price is $50.55 and its 200-day moving average price is $58.27. The company has a market capitalization of $8.47 billion, a PE ratio of -8.19 and a beta of 1.25. The company has a quick ratio of 1.93, a current ratio of 2.15 and a debt-to-equity ratio of 0.97.

Exact Sciences (NASDAQ:EXAS) last posted its quarterly earnings data on Wednesday, February 19th. The medical research company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.29) by $0.23. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. The business had revenue of $713.42 million for the quarter, compared to the consensus estimate of $701.45 million. On average, equities analysts anticipate that Exact Sciences Co. will post -0.58 EPS for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on EXAS shares. William Blair reissued an “outperform” rating on shares of Exact Sciences in a research report on Thursday, February 20th. Scotiabank boosted their target price on Exact Sciences from $70.00 to $73.00 and gave the company a “sector outperform” rating in a research report on Monday, February 24th. Piper Sandler decreased their target price on Exact Sciences from $75.00 to $70.00 and set an “overweight” rating for the company in a research report on Wednesday, February 26th. TD Cowen boosted their target price on Exact Sciences from $82.00 to $86.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Finally, Benchmark reaffirmed a “buy” rating and issued a $65.00 target price on shares of Exact Sciences in a research report on Monday, January 13th. Two research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $70.83.

About Exact Sciences

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.